Pavelek Zbyšek, Souček Ondřej, Krejsek Jan, Součková Ilona, Popovičová Andrea, Matyáš David, Sobíšek Lukáš, Novotný Michal
Department of Neurology, Faculty of Medicine in Hradec Králové, Charles University, 50005 Hradec Králové, Czech Republic.
Department of Neurology, University Hospital Hradec Králové, 50005 Hradec Králové, Czech Republic.
Int J Mol Sci. 2025 Sep 8;26(17):8750. doi: 10.3390/ijms26178750.
The transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) is characterized by an increasing neurodegenerative component. Identifying biomarkers that distinguish these disease stages is crucial for early diagnosis and treatment optimization. This study aimed to compare serum levels of progranulin, interleukin-6 (IL-6), semaphorin 3A (SEMA3A), and neurofilaments between RRMS and SPMS patients and to investigate their correlation with clinical characteristics, including disability measured by the Expanded Disability Status Scale (EDSS). This observational study included 118 MS patients (63 RRMS and 55 SPMS). Serum biomarker levels were measured using an enzyme-linked immunosorbent assay (ELISA). Statistical analyses included group comparisons using non-parametric tests and correlation analyses using Pearson's correlation coefficient with multiple testing corrections. While demographic and clinical parameters significantly differed between groups ( < 0.001), biomarker levels showed no statistically significant differences ( > 0.05). However, in SPMS patients, SEMA3A correlated positively with neurofilaments (r = 0.359, = 0.007), and progranulin correlated with IL-6 (r = 0.354, = 0.008). No significant biomarker correlations with EDSS were found. Although absolute biomarker levels did not distinguish RRMS from SPMS, specific biomarker correlations may reflect processes relevant to disease progression and warrant further longitudinal validation.
复发缓解型多发性硬化症（RRMS）向继发进展型多发性硬化症（SPMS）的转变以神经退行性成分增加为特征。识别区分这些疾病阶段的生物标志物对于早期诊断和优化治疗至关重要。本研究旨在比较RRMS和SPMS患者血清中前颗粒蛋白、白细胞介素-6（IL-6）、信号素3A（SEMA3A）和神经丝的水平，并研究它们与临床特征的相关性，包括通过扩展残疾状态量表（EDSS）测量的残疾情况。这项观察性研究纳入了118例MS患者（63例RRMS和55例SPMS）。使用酶联免疫吸附测定（ELISA）测量血清生物标志物水平。统计分析包括使用非参数检验进行组间比较，以及使用Pearson相关系数并进行多重检验校正的相关性分析。虽然两组之间的人口统计学和临床参数存在显著差异（<0.001），但生物标志物水平无统计学显著差异（>0.05）。然而，在SPMS患者中，SEMA3A与神经丝呈正相关（r = 0.359，= 0.007），前颗粒蛋白与IL-6呈正相关（r = 0.354，= 0.008）。未发现生物标志物与EDSS有显著相关性。虽然生物标志物的绝对水平不能区分RRMS和SPMS，但特定的生物标志物相关性可能反映了与疾病进展相关的过程，值得进一步进行纵向验证。
